Activity of Cannabinoids in Type II Diabetes
DOI:
https://doi.org/10.37591/rrjon.v7i2.955Abstract
The present research is a theoretical study of the medicinal use of Cannabis (cannabinoids) compounds in Type II Diabetes based on literature citing animal models and available clinical evidence from human studies. The study emphasizes the positive physiological actions and benefits of cannabinoid compounds in Type II Diabetes. The pharmacological activities of cannabinoid compounds in Type II Diabetes have been studies only in limited human clinical trials that were often not conducted as evidence-based (i.e., following the established rules of probability and scientific methodology). In the United States, the Federal Drug Enforcement Agency (DEA) continues to classify all natural cannabinoid compounds as “Schedule 1” drugs (i.e., dangerous illegal narcotics on par with heroin or LSD). As a result of this classification as illegal, many human clinical studies of Cannabis compounds in medical therapy have been thwarted and continue to face a dearth of funding for research grants and drug development by the pharmaceutical houses, universities, and industry. The future looks bright, though, for Cannabis as a medication source as many states (including all the U.S. western states) have decriminalized the drug in legislation popularly known as “medical marijuana” or “recreational marijuana”. Cannabis compounds and derivatives hold strong promise to add to the pharmacopeia of medicines employed in human healthcare that would expand alternatives of medical treatment modes.
Keywords: CBD, Delta9-THC, Type II Diabetes, anti-inflammatory activity, psychogenic effects
Cite this Article
P. Flaer. Activity of Cannabinoids in Type II Diabetes. Research and Reviews: Journal of Neuroscience. 2017; 7(2): 1–5p.
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |
